1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | C57BL/6 Mouse |
Cat.No | ABC-H0077X |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Spleen Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Spleen |
Disease | Normal |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Mouse Primary Cells |
C57BL/6 Mouse CD3 Pan T Cells from adult C57BL/6 mice are primary immune cells isolated from the spleen of SPF-grade, healthy animals. These cells represent around 33% of the total splenic lymphocyte population and include both CD4⁺ and CD8⁺ T cells. They are identified by the expression of the CD3 surface antigen and the T cell receptor (TCR), which enables them to recognize antigens presented via major histocompatibility complex molecules. Typically, they are non-adherent, grow in suspension, and do not proliferate without activation stimuli. CD3 pan T cells are not passaged and are used fresh. No karyotype analysis is performed due to their primary nature. The cells are confirmed negative for HIV-1, HIV-2, and HCV, and are widely applied in immunological, autoimmune disease, and transplantation research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
C57BL/6 CD3 pan T cells are derived from the mouse strain act as important in vitro models for investigating T cell biology and their central functions in immunity. These T cells play a pivotal role in cytokine production and cytotoxicity. Therefore, pan T cells are employed in stimulation-dependent functional experiments that evaluate cytokine production, proliferation, and cytotoxicity. Given the current focus on immuno-modulatory drug development, purified C57BL/6 mouse CD3 pan T cells provide an optimal cell population for assessing T cell responses during the preclinical phase of therapeutic molecule development.